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Dear Editor
With great interest we read the recent article by Wang et al.
in Pulmonary Circulation presenting a meta-analysis on the
eﬃcacy and safety of pulmonary vasodilator therapy in
patients with a Fontan circulation.1 We commend the
authors with this thorough attempt to provide an overview
of the available evidence on this important and controversial
topic. The authors report that they have performed a meta-
analysis of randomized controlled trials (RCTs) and con-
clude that pulmonary vasodilator therapy, although not
reducing mortality, improves peak oxygen consumption
(pVO2), hemodynamics, and 6-min walking distance
(6MWD) and reduces NYHA functional class statistically
signiﬁcantly based on nine studies.
After thorough assessment of the manuscript and con-
sidering the increased interest for the use of pulmonary
vasodilator therapy in Fontan patients, we feel the necessity
to express our concerns regarding the claims and conclu-
sions drawn by the authors. Meta-analyses can be a valuable
tool to assess systematically available information from dif-
ferent studies in order to derive conclusions from the total
body of research. However, it cannot provide evidence that
is not there. The current meta-analysis includes extremely
heterogeneous data from a limited number of studies with
signiﬁcant clinical and methodological diversity. When sub-
stantial heterogeneity exists, pooling data from multiple
trials and presenting a single summary estimate can be mis-
leading and should be avoided.2
There are several important points to take into consider-
ation when interpreting this meta-analysis. First, concerning
inclusion criteria; two of the included studies are not RCTs
(one retrospective design and one prospective design with a
historical cohort control group) and thus in fact do not fulﬁll
the authors’ inclusion criteria of RCT-only studies.3,4
Without these two studies there is only one RCT reporting
on mean pulmonary artery pressure (mPAP)5 and only RCT
data from one medical center onmortality,5,6 making a meta-
analysis on hemodynamics and mortality a futile attempt.
As a consequence, no meaningful conclusions can be drawn
considering mPAP and mortality. Furthermore, data and
conclusions regarding 6MWDoutcomes are from two studies
from one and the same center, with identical treatment proto-
cols and likely to have overlapping patient populations.
Therefore, a meta-analysis applied on these data can be
questioned.5,6
Second, concerning study population and time of treat-
ment, four of the included studies concern pediatric patients
only and, more importantly, three of these study the eﬀect of
pulmonary vasodilators in the immediate perioperative
period of the Fontan-procedure.3,4,6 In contrast, the remain-
ing ﬁve studies include adult patients at mid-term to long-
term follow-up after the Fontan procedure. In our opinion,
these studies cannot be compared side-by-side since the
pathophysiology and eﬃcacy variables are completely dif-
ferent in both situations. Further, the meta-analysis includes
studies assessing the eﬀect of a single drug dose and those
assessing the eﬀect of maintenance therapy. When pooling
studies with such heterogeneity in patient population,
timing, and duration of treatment, one compares apples to
oranges.
Third, regarding pVO2, of the ﬁve studies, only
three studies found a small increase in pVO2 (1.4, 1.7,
1.8mL/kg/min) whereas the two other studies did not
show any improvement (0 and 1mL/kg/min pVO2).
Most importantly, the study reporting a 1.8mL/kg/min
increase was actually a cross-sectional study including a
single dose of sildenaﬁl between two cardiopulmonary exer-
cise tests (CPETs) on the same day.7 This study (with an
assigned weight of 67%) mainly determined the pooled esti-
mate outcome of 1.42mL/kg/min improvement in pVO2.
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Although these results are all interesting and of individual
value, one should critically question whether the reported
eﬀect sizes on pVO2 are valid and represent a clinically sig-
niﬁcant improvement. In this journal,8 Lammers and Humpl
speak their minds and express the hope that the results from
the presented meta-analysis will encourage clinicians to con-
sider pulmonary vasodilator therapy for selected Fontan
patients, irrespective of the current absence of a recommen-
dation in the ESC guidelines.9 In the perspective, outlined
above, we feel this encouragement is premature and not
supported by the currently available data: the evidence is
simply not there (yet).
One must keep in mind that pulmonary vasodilator ther-
apy, originally approved for the treatment of pulmonary
arterial hypertension (PAH), is aimed to stimulate endothe-
lial-derived vaso-relaxation factors resulting in relaxation of
the vascular smooth muscle cells (VSMCs) leading to vaso-
dilation which reduces pulmonary vascular resistance.
Pulmonary vascular remodeling in long-term Fontan
patients has been shown to have a strikingly diﬀerent pat-
tern compared to that in PAH. The latter pattern is char-
acterized by VSMC proliferation, whereas in Fontan
patients a pattern of progressive medial atrophy with a
loss of VSMCs and eccentric luminal ﬁbrosis has been
observed.10 These observations challenge the concept that
the beneﬁcial eﬀects of pulmonary vasodilator therapy in
PAH can be translated to patients with a lasting Fontan
circulation.
At best, the current meta-analysis may support the sug-
gestion for beneﬁcial short-term eﬀects of pulmonary vaso-
dilator therapy in selected patients with a Fontan
circulation. The conclusions as drawn by the authors
highly overrate the available evidence which is misleading.
In the near future, the results from the ongoing RUBATO
(NCT03153137) and FUEL (NCT02741115) trials may pro-
vide more evidence on the eﬃcacy of pulmonary vasodilator
therapy in Fontan patients. Given the paucity of therapeutic
options for the failing Fontan patient, it may be tempting to
surrender to hopeful or wishful thinking. However, for now
we want to warn to stay critical on this matter in order not
to misperceive pulmonary vasodilator therapy for Fontan
patients as the proverbial new clothes of the Emperor.
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